News

The decision followed the Positive Opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on March 26 2015 and is applicable to all 28 European

The tablets are an alternative to Mucinex D (Guaifenesin/pseudoephedrine tablets), an expectorant indicated to relieve chest congestion and make coughs more productive. Perrigo will begin shipment of these

The research collaboration will advance the development of the French firm’s lead product candidate in AML, called UCART123. The deal will combine Weill Cornell’s expertise and resources in

Orphan drug status will provide the company with certain financial benefits such as tax credits for clinical trials, and waiver of prescription drug user fee for the marketing

The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat

The intellectual property related to the panel will also be obtained by the company. Upon execution of the license, Genmab will make a one-time $4m licensing payment to

The recommendation for this combination follows a review by the NHS and Care Excellence (NICE). The combination therapy is indicated for patients with non-small cell lung cancer (NSCLC)

Perrigo will acquire rights to the nicotine replacement therapies of both GSK and Novartis, NiQuitin and Nicotinell. Novartis’s cold sore management products in the EEA and cold and

Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government’s repository of critical medical supplies for biowarfare preparedness. Anthim has been developed under